Yes, GCP says you must file signed agreements between investigators and service providers. But while everyone talks about the Clinical Trial Agreement (CTA), hardly anyone mentions the Material Transfer Agreement (MTA). And while GCP tells us to document the collection, processing, and shipment of biological samples, no one warns you that if those samples are crossing borders, you may need an export permit. These records are the hidden essentials – the who, what, why, and how that only surface when it’s suddenly your responsibility to sort them out.
What are MTAs and export permits?
An MTA is the legal handshake between the site (through the Principal Investigator, PI) and the receiving laboratory. It defines who owns the samples, how they’ll be used, and what happens to them after analysis.
The export permit, meanwhile, is the regulatory green light that allows those samples to leave the country.
One without the other, and your shipment may be stopped before it even begins.
Where do you find the clues to these records?
The first hints usually appear in the Informed Consent Form (ICF).
Look closely and you may notice that participant samples will be sent overseas, often with the full address of the receiving lab listed. This isn’t just courtesy – it’s a regulatory requirement.
Participants must be informed if their personal information or biological material will be shared outside the site, with whom it will be shared, and for what purpose. Under frameworks like POPIA, HIPAA, and GDPR, biological samples are considered personal identifiers. That means participants have the right to know not only that their samples will be shipped abroad, but also how their data will be protected, who will access it, and what will ultimately happen to it.
The protocol or lab manual will confirm the processing details. Behind the scenes, the MTA lays down the legal conditions, while the export permit – if required – translates those agreements into government authorisation.
Who signs what?
The PI is the key figure.
They sign the MTA on behalf of the site, while the recipient lab signs on their end. When it comes to the export permit, the PI is also the applicant. The permit is then issued by the relevant authority, depending on the country – whether that’s the Department of Health (SA), a ministry (EU), or the Centres for Disease Control and Prevention (CDC) in the US.
What do these documents actually contain?
An MTA stipulates:
- the protocol number and title
- the type of samples (for example, urine biomarkers)
- the purpose of analysis (say, assessing safety and tolerability of the investigational product)
- the names and addresses of both sender and recipient
The export permit goes a step further. It requires the ethics approval letter with valid dates, the signed MTA, and a completed application form. That form details:
- the type of sample
- the sample volume
- the shipment timeline
Example:
2 site visits × 10 ml sample per visit × 50 participants = 1000 ml total.
The permit also specifies the export period, such as November 2025 to November 2026.
Where do these records live in the files?
MTAs belong in the Investigator Site File (ISF) and the Trial Master File (TMF), right next to the CTA. Export permits, biosafety certificates, and shipping manifests join them there or will be filed with the collection, processing logs and shipment docs.
Together, they complete the chain of custody, showing how every sample moved from participant to lab.
Where does the CRA fit in?
CRAs are the final checkpoint before any box leaves the site. That means:
A monitor is responsible for checking whether the details on the export permit match reality:
- The destination lab
- The type of samples transported
- The total sample volume
- Whether the export permit is still valid. Permits contain an expiration date and once the approved sample volume is used up, no further shipments can be made.
Keeping track of these records is no glamorous activity, but it prevents shipments from being blocked at borders – or worse, entire studies from stalling.
It’s easy to dismiss MTAs and export permits as “just paperwork.” But when you see them for what they really are – hidden essentials that protect participants, sites, and sponsors – you understand their true weight.
Testimony to the essential nature of these hidden records
During a monitoring visit, one can walk into a site to find boxes of samples waiting in the freezer. Everything is packed, labelled, and ready to be shipped.
The only problem?
The export permit had expired two weeks prior to the visit date. The courier cannot touch the shipment. The sponsor is furious. And the site?
They have to start the application process from scratch.
It delays the study by months, all because of a date no one double-checked.
Moral of the story?
MTAs and export permits may not get the spotlight, but they can make or break a trial. Next time one lands on your desk, treat it with the seriousness it deserves.
If you are serious about truly understanding essential records – including the hidden ones – be on the lookout for TASK Research Academy’s course:
Mastering Essential Records in Clinical Trials, launching soon!
